Eris Lifesciences share news and announcements
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,095.50down ₹25.70 (2.29%)BSE ₹1,097.65
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,121.20.
52-week range of traded prices to 23 Oct 2026
₹1,087.90Low, 23 Oct 2026₹1,740.00High, 9 Dec 2025
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,199 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 Jul 2026
- 23.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.66%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 Jul 2026
- 19.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 29 Jul 2026
- 13.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.59
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 37,94348.8% delivered
Eris Lifesciences analyst meets
371 filed, newest first. Page 3 of 8.
Jan 2023
14 Jan · Analysts
4 Jan · Analysts
Dec 2022
20 Dec · Analysts
Nov 2022
Oct 2022
Sep 2022
Aug 2022
Jul 2022
Jun 2022
May 2022
Apr 2022
Mar 2022
Feb 2022
18 Feb · Analysts
16 Feb · Analysts
15 Feb · Analysts
9 Feb · Analysts
8 Feb · Analysts
4 Feb · Analysts
2 Feb · Analysts
Jan 2022
20 Jan · Analysts
19 Jan · Analysts
18 Jan · Analysts
13 Jan · Analysts
7 Jan · Analysts
Dec 2021
22 Dec · Analysts
22 Dec · Analysts
3 Dec · Analysts
Nov 2021
26 Nov · Analysts
18 Nov · Analysts
16 Nov · Analysts
16 Nov · Analysts
1 Nov · Analysts
1 Nov · Analysts
Oct 2021
22 Oct · Analysts
21 Oct · Analysts